Progranulin (PGRN) is involved in wound repair

No abstract

Mutations in the small heat shock protein Hsp27, encoded by the HSPB1 gene, have been shown to cause Charcot Marie Tooth Disease type 2 (CMT-2) or distal hereditary motor neuropathy (dHMN). Protein aggregation and axonal transport deficits have been implicated in the disease. In this study, we conducted analysis of bidirectional movements of mitochondria in primary motor neuron axons expressing wild type and mutant Hsp27. We found significantly slower retrograde transport of mitochondria in Ser135Phe, Pro39Leu and Arg140Gly mutant Hsp27 expressing motor neurons than in wild type Hsp27 neurons, although anterograde movement velocities remained normal. Retrograde transport of other important cargoes, such as the p75 neurotrophic factor receptor was minimally altered in mutant Hsp27 neurons, implicating that axonal transport deficits primarily affect mitochondria and the axonal transport machinery itself is less affected. Investigation of mitochondrial function revealed a decrease in mitochondrial membrane potential in mutant Hsp27 expressing motor axons, as well as a reduction in mitochondrial complex 1 activity, increased vulnerability of mitochondria to mitochondrial stressors, leading to elevated superoxide release and reduced mitochondrial glutathione (GSH) levels, although cytosolic GSH remained normal. This mitochondrial redox imbalance in mutant Hsp27 motor neurons is likely to cause low level of oxidative stress, which in turn will contribute to, and indeed may be the underlying cause of the deficits in mitochondrial axonal transport. Together, these findings suggest that the mitochondrial abnormalities in mutant Hsp27-induced neuropathies may be a primary cause of pathology, leading to further deficits in the mitochondrial axonal transport and onset of disease.

Here, we describe the generation and characterization of a novel tau transgenic mouse model (mTau) that overexpresses wild-type murine tau protein by twofold compared with endogenous levels. Transgenic tau expression was driven by a BAC transgene containing the entire wild-type mouse tau locus, including the endogenous promoter and the regulatory elements associated with the tau gene. The mTau model therefore differs from other tau models in that regulation of the genomic mouse transgene mimics that of the endogenous gene, including normal exon splicing regulation. Biochemical data from the mTau mice demonstrated that modest elevation of mouse tau leads to tau hyperphosphorylation at multiple pathologically relevant epitopes and accumulation of sarkosyl-insoluble tau. The mTau mice show a progressive increase in hyperphosphorylated tau pathology with age up to 15 to 18 months, which is accompanied by gliosis and vacuolization. In contrast, older mice show a decrease in tau pathology levels, which may represent hippocampal neuronal loss occurring in this wild-type model. Collectively, these results describe a novel model of tauopathy that develops pathological changes reminiscent of early stage Alzheimer's disease and other related neurodegenerative diseases, achieved without overexpression of a mutant human tau transgene. This model will provide an important tool for understanding the early events leading to the development of tau pathology and a model for analysis of potential therapeutic targets for sporadic tauopathies. Abnormal accumulation of the microtubule-associated protein tau, in the form of neurofibrillary tangles (NFTs), is the defining pathological feature of neurodegenerative diseases termed tauopathies. Six major tau protein isoforms are generated in adult human brain by alternative splicing of the tau (MAPT) gene, 1,2 and studies of mutations within this gene have provided insight into potential mechanisms for the pathological aggregation of tau proteins.3,4 With use of a single isoform of mutant human tau, transgenic mice have been generated (reviewed in 5 ) that recapitulate many features of human tauopathy; however, most tauopathies are not associated with specific MAPT mutations. Because normal and mutant tau proteins appear to have functional differences, 6 -8 the mechanism of tau pathology development, neuronal loss, and interactions with other proteins may also differ between sporadic tauopathies and cases linked to specific mutations. Previous attempts to create a wild-type tauopathy model through overexpression of a single wild-type human tau isoform have generally led to minimal pathological changes. Although these models have been useful in studying early aspects of tauopathy, they do not mimic normal gene regulation or tau isoform profiles in the brain. Development of a mouse model overexpressing the entire human tau transgene (8c mice) was expected to overcome this limitation. However, these mice failed to elicit notable tau pathology, but did result in a significant shift in exon 10...